Doxil® — The first FDA-approved nano-drug: Lessons learned

Barenholz, 2012, Doxil®—the first FDA-approved nano-drug: from an idea to a product, 335

Gabizon, 1983, Enhancement of adriamycin delivery to liver metastatic cells with increased tumoricidal effect using liposomes as drug carriers, Cancer Res., 43, 4730

Gabizon, 1985, Superior therapeutic activity of liposome-associated adriamycin in a murine metastatic tumour model, Br. J. Cancer, 51, 681, 10.1038/bjc.1985.103

Gabizon, 1986, Comparative long-term study of the toxicities of free and liposome-associated doxorubicin in mice after intravenous administration, J. Natl. Cancer Inst., 77, 459

Gabizon, 1986, Design, characterization and anti-tumor activity of adriamycin-containing phospholipid vesicles, 229

Gabizon, 1988, Investigations on the antitumor efficacy of liposome-associated doxorubicin in murine tumor models, Isr. J. Med. Sci., 24, 512

Gabizon, 1988, Adriamycin-containing liposomes in cancer chemotherapy, 365

Gabizon, 1989, Systemic administration of doxorubicin-containing liposomes in cancer patients: a phase I study, Eur. J. Cancer Clin. Oncol., 25, 1795, 10.1016/0277-5379(89)90350-7

Gabizon, 1989, Liposome-associated doxorubicin: preclinical pharmacology and exploratory clinical phase, 391

Goren, 1990, The influence of physical characteristics of liposomes containing doxorubicin on their pharmacological behavior, Biochim. Biophys. Acta, 1029, 285, 10.1016/0005-2736(90)90165-K

D. Goren, Liposomes as doxorubicin carriers: a means to improve the therapeutic index of the drug, in: Ph.D. Thesis, Hebrew University of Jerusalem, Israel, 1990.

Amselem, 1993, A large-scale method for the preparation of sterile and nonpyrogenic liposomal formulations of defined size distributions for clinical use, vol. 1, 501

Gabizon, 1988, Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors, Proc. Natl. Acad. Sci. U. S. A., 85, 6949, 10.1073/pnas.85.18.6949

Gabizon, 1991, Pharmacokinetic and imaging studies in patients receiving a formulation of liposome-associated adriamycin, Br. J. Cancer, 64, 1125, 10.1038/bjc.1991.476

Amselem, 1993, In vitro tests to predict in vivo performance of liposomal dosage forms, Chem. Phys. Lipids, 64, 219, 10.1016/0009-3084(93)90067-D

Barenholz, 1993, Quality control assays in the development and clinical use of liposome-based formulations, vol. 1, 527

Barenholz, 1993, Stability of liposomal doxorubicin formulations: problems and prospects, Med. Res. Rev., 13, 449, 10.1002/med.2610130404

Barenholz, 1995, Rational design of amphiphile-based drug carriers and sterically stabilized carriers, J. Liposome Res., 5, 905, 10.3109/08982109509012690

Barenholz, 2003, Relevancy of drug loading to liposomal formulation therapeutic efficacy, J. Liposome Res., 13, 1, 10.1081/LPR-120017482

Barenholz, 2001, Liposome application: problems and prospects, Curr. Opin. Colloid Interface Sci., 6, 66, 10.1016/S1359-0294(00)00090-X

Szebeni, 2007, Animal models of complement-mediated hypersensitivity reactions to liposomes and other lipid-based nanoparticles, J. Liposome Res., 17, 107, 10.1080/08982100701375118

Szebeni, 2011, Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention, Adv. Drug Deliv. Rev., 63, 1020, 10.1016/j.addr.2011.06.017

Szebeni, 2011, Liposome-induced complement activation and related cardiopulmonary distress in pigs: factors promoting reactogenicity of Doxil and Am Bisome, Nanomedicine, 8, 176, 10.1016/j.nano.2011.06.003

Hwang, 1987, Liposome pharmacokinetics, 109

Matsumura, 1986, A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs, Cancer Res., 46, 6387

Maeda, 2009, Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect, Eur. J. Pharm. Biopharm., 71, 409, 10.1016/j.ejpb.2008.11.010

Poste, 1982, Analysis of the fate of systemically administered liposomes and implications for their use in drug delivery, Cancer Res., 42, 1412

Poste, 1983, Liposome targeting in vivo: problems and opportunities, Biol. Cell, 47, 19

Blum, 1974, Adriamycin. A new anticancer drug with significant clinical activity, Ann. Intern. Med., 80, 249, 10.7326/0003-4819-80-2-249

McKelvey, 1976, Hydroxyldaunomycin (adriamycin) combination chemotherapy in malignant lymphoma, Cancer, 38, 1484, 10.1002/1097-0142(197610)38:4<1484::AID-CNCR2820380407>3.0.CO;2-I

Gundersen, 1986, Weekly adriamycin versus VAC in advanced breast cancer. A randomized trial, Eur. J. Cancer Clin. Oncol., 22, 1431, 10.1016/0277-5379(86)90075-1

Zucker, 2009, Liposome drugs' loading efficiency: a working model based on loading conditions and drug's physicochemical properties, J. Control. Release, 139, 73, 10.1016/j.jconrel.2009.05.036

A. Cern, A. Golbraikh, A. Sedykh, A. Tropsha, Y. Barenholz, A. Goldblum, Quantitative Structure–property Relationship Modeling of Remote Liposome Loading of Drugs, J. Control. Release. (2012, this issue).

Barenholz, 2007, Amphipathic weak base loading into preformed liposomes having a transmembrane ammonium ion gradient: From the bench to approved DOXIL, vol. 2, 1

Rahman, 1980, Liposomal protection of adriamycin-induced cardiotoxicity in mice, Cancer Res., 40, 1532

Rahman, 1985, Pharmacological, toxicological, and therapeutic evaluation in mice of doxorubicin entrapped in cardiolipin liposomes, Cancer Res., 45, 796

Rahman, 1986, Antitumor and toxicity evaluation of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes, Cancer Chemother. Pharmacol., 16, 22, 10.1007/BF00255281

Rahman, 1986, Comparative pharmacokinetics of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes, Cancer Res., 46, 2295

Weiss, 1992, The anthracyclines: will we ever find a better doxorubicin?, Semin. Oncol., 19, 670

Skeel, 1999

Minotti, 2004, Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity, Pharmacol. Rev., 56, 185, 10.1124/pr.56.2.6

Kenyon, 2010, Chemotherapy and cardiac toxicity — the lesser of two evils

Peng, 2005, The cardiotoxicology of anthracycline chemotherapeutics: translating molecular mechanism into preventative medicine, Mol. Interv., 5, 163, 10.1124/mi.5.3.6

Takimoto, 2008, Principles of oncologic pharmacotherapy

Beijnen, 1985, Stability of anthracycline antitumour agents in infusion fluids, J. Parenter. Sci. Technol., 39, 220

Andrews, 1980, Facile and definitive determination of human adriamycin and daunoribicin metabolites by high-pressure liquid chromatography, Drug Metab. Dispos., 8, 152

Garbuzenko, 2005, Effect of grafted PEG on liposome size and on compressibility and packing of lipid bilayer, Chem. Phys. Lipids, 135, 117, 10.1016/j.chemphyslip.2005.02.003

Haran, 1993, Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases, Biochim. Biophys. Acta, 1151, 201, 10.1016/0005-2736(93)90105-9

Bandak, 1999, Reduced UV-induced degradation of doxorubicin encapsulated in polyethyleneglycol-coated liposomes, Pharm. Res., 16, 841, 10.1023/A:1018869818282

Gabizon, 1994, Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes, Cancer Res., 54, 987

Gabizon, 2003, Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies, Clin. Pharmacokinet., 42, 419, 10.2165/00003088-200342050-00002

Hashizume, 2000, Openings between defective endothelial cells explain tumor vessel leakiness, Am. J. Pathol., 156, 1363, 10.1016/S0002-9440(10)65006-7

Bassermann, 1986, Changes of vascular pattern of tumors and surrounding tissue during different phases of metastatic growth, Recent Results Cancer Res., 100, 256, 10.1007/978-3-642-82635-1_32

Jain, 1987, Transport of molecules across tumor vasculature, Cancer Metastasis Rev., 6, 559, 10.1007/BF00047468

Y. Barenholz, G. Haran, Efficient Loading and Controlled Release of Amphipathic Molecules, in, United States Patent 5,244,544, 1994.

Y. Barenholz, G. Haran, Method of Amphipathic Drug Loading in Liposomes by pH Gradient, in, United States Patent 5,192,549, 1993.

Deamer, 1972, The response of fluorescent amines to pH gradients across liposome membranes, Biochim. Biophys. Acta, 274, 323, 10.1016/0005-2736(72)90180-0

Nichols, 1976, Catecholamine uptake and concentration by liposomes maintaining pH gradients, Biochim. Biophys. Acta, 455, 269, 10.1016/0005-2736(76)90169-3

Madden, 1990, Incorporation of amphotericin B into large unilamellar vesicles composed of phosphatidylcholine and phosphatidylglycerol, Chem. Phys. Lipids, 52, 189, 10.1016/0009-3084(90)90114-7

Bolotin, 1994, Ammonium sulfate gradients for efficient and stable remote loading of amphipathic weak bases into liposomes and ligandoliposomes, J. Liposome Res., 4, 455, 10.3109/08982109409037057

Lasic, 1995, Transmembrane gradient driven phase transitions within vesicles: lessons for drug delivery, Biochim. Biophys. Acta, 1239, 145, 10.1016/0005-2736(95)00159-Z

R. Ulmansky, K. Turjeman, M. Baru, G. Katzavian, M. Harel, A. Sigal, Y. Naparstak, Y. Barenholz, Glucocorticoids in nano-liposomes administered intravenously and subcutaneously to adjuvant arthritis rats are superior to the free drugs in suppressing arthritis and inflammatory cytokines, J. Control. Release. (2012, this issue).

Clerc, 1998, A quantitative model for using acridine orange as a transmembrane pH gradient probe, Anal. Biochem., 259, 104, 10.1006/abio.1998.2639

Wasserman, 2007, The antioxidant tempamine: in vitro antitumor and neuroprotective effects and optimization of liposomal encapsulation and release, Langmuir, 23, 1937, 10.1021/la060218k

Stein, 1986

Grant, 2001, DRV liposomal bupivacaine: preparation, characterization, and in vivo evaluation in mice, Pharm. Res., 18, 336, 10.1023/A:1011059131348

Lasic, 1992, Gelation of liposome interior. A novel method for drug encapsulation, FEBS Lett., 312, 255, 10.1016/0014-5793(92)80947-F

Abra, 2002, The next generation of liposome delivery systems: recent experience with tumor-targeted, sterically-stabilized immunoliposomes and active-loading gradients, J. Liposome Res., 12, 1, 10.1081/LPR-120004770

Horowitz, 1992, In vitro cytotoxicity of liposome-encapsulated doxorubicin: dependence on liposome composition and drug release, Biochim. Biophys. Acta, 1109, 203, 10.1016/0005-2736(92)90084-Y

A.A. Gabizon, Y. Barenholz, Method for Drug Loading in Liposomes, in, International Patent Appl., WO/2005/046643, 2005.

Grant, 2004, A novel liposomal bupivacaine formulation to produce ultralong-acting analgesia, Anesthesiology, 101, 133, 10.1097/00000542-200407000-00021

R. Cohen, H. Kanaan, G.J. Grant, Y. Barenholz, Prolonged analgesia from Bupisome and Bupigel formulations: from design and fabrication to improved stability, J. Control. Release. (2012, this issue).

Lasic, 1999, Sterically stabilized liposomes in cancer therapy and gene delivery, Curr. Opin. Mol. Ther., 1, 177

Peleg-Shulman, 2001, Characterization of sterically stabilized cisplatin liposomes by nuclear magnetic resonance, Biochim. Biophys. Acta, 1510, 278, 10.1016/S0005-2736(00)00359-X

Schroeder, 2009, Ultrasound triggered release of cisplatin from liposomes in murine tumors, J. Control. Release, 137, 63, 10.1016/j.jconrel.2009.03.007

Allen, 1987, Large unilamellar liposomes with low uptake into the reticuloendothelial system, FEBS Lett., 223, 42, 10.1016/0014-5793(87)80506-9

T.M. Allen, Liposomes with Enhanced Circulation Time, in, United States Patent 4,837,028, 1989.

M.C. Woodle, F.J. Martin, A. Yau-Yang, C.T. Redmann, Liposomes with Enhanced Circulation Time, in, United States Patent 5,013,556, 1991.

Woodle, 1990, Improved long circulating (Stealth®) liposomes using synthetic lipids, 77

Woodle, 1992, Sterically stabilized liposomes, Biochim. Biophys. Acta, 1113, 171, 10.1016/0304-4157(92)90038-C

Woodle, 1993, Surface-modified liposomes: assessment and characterization for increased stability and prolonged blood circulation, Chem. Phys. Lipids, 64, 249, 10.1016/0009-3084(93)90069-F

C.A. Hunt, D.P. Papahadjopoulous, Method for Producing Liposomes in Selected Size Range, in, United States Patent 4,529,561, 1985.

Klibanov, 1990, Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes, FEBS Lett., 268, 235, 10.1016/0014-5793(90)81016-H

Blume, 1990, Liposomes for the sustained drug release in vivo, Biochim. Biophys. Acta, 1029, 91, 10.1016/0005-2736(90)90440-Y

1995

Abuchowski, 1977, Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase, J. Biol. Chem., 252, 3582, 10.1016/S0021-9258(17)40292-4

Veronese, 2002, Introduction and overview of peptide and protein pegylation, Adv. Drug Deliv. Rev., 54, 453, 10.1016/S0169-409X(02)00020-0

Veronese, 2005, PEGylation, successful approach to drug delivery, Drug Discov. Today, 10, 1451, 10.1016/S1359-6446(05)03575-0

Tirosh, 1997, Oxidative stress effect on the integrity of lipid bilayers is modulated by cholesterol level of bilayers, Chem. Phys. Lipids, 87, 17, 10.1016/S0009-3084(97)00019-4

Tirosh, 1998, Hydration of polyethylene glycol-grafted liposomes, Biophys. J., 74, 1371, 10.1016/S0006-3495(98)77849-X

Allen, 1995, From fusion to magic bullets: the influence of Dimitri Papahdjopoulos, J. Liposome Res., 5, 657, 10.3109/08982109509012671

Gabizon, 1993, Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid: pharmacokinetic studies in rodents and dogs, Pharm. Res., 10, 703, 10.1023/A:1018907715905

Emanuel, 1996, Preparation and characterization of doxorubicin-loaded sterically stabilized immunoliposomes, Pharm. Res., 13, 352, 10.1023/A:1016028106337

Emanuel, 1996, Targeted delivery of doxorubicin via sterically stabilized immunoliposomes: pharmacokinetics and biodistribution in tumor-bearing mice, Pharm. Res., 13, 861, 10.1023/A:1016096910822

Garbuzenko, 2005, Electrostatics of PEGylated micelles and liposomes containing charged and neutral lipopolymers, Langmuir, 21, 2560, 10.1021/la0479105

Symon, 1999, Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes, Cancer, 86, 72, 10.1002/(SICI)1097-0142(19990701)86:1<72::AID-CNCR12>3.0.CO;2-1

Druckmann, 1989, Separation of liposome-associated doxorubicin from non-liposome-associated doxorubicin in human plasma: implications for pharmacokinetic studies, Biochim. Biophys. Acta, 980, 381, 10.1016/0005-2736(89)90329-5

Amselem, 1990, Optimization and upscaling of doxorubicin-containing liposomes for clinical use, J. Pharm. Sci., 79, 1045, 10.1002/jps.2600791202

Solomon, 2008, Clinical pharmacology of liposomal anthracyclines: focus on pegylated liposomal Doxorubicin, Clin. Lymphoma Myeloma, 8, 21, 10.3816/CLM.2008.n.001

Gabizon, 1995, Doxorubicin encapsulated in polyethylene-glycol coated liposomes: initial clinical-pharmacokinetic studies in solid tumors, 245

Jain, 2007, Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model, Cancer Res., 67, 2729, 10.1158/0008-5472.CAN-06-4102

Jain, 1987, Transport of molecules in the tumor interstitium: a review, Cancer Res., 47, 3039

Schroeder, 2009, Ultrasound, liposomes, and drug delivery: principles for using ultrasound to control the release of drugs from liposomes, Chem. Phys. Lipids, 162, 1, 10.1016/j.chemphyslip.2009.08.003

Zamboni, 2004, Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma, Cancer Chemother. Pharmacol., 53, 329, 10.1007/s00280-003-0719-4

Meerum Terwogt, 2002, Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin, Cancer Chemother. Pharmacol., 49, 201, 10.1007/s002800100371

Veal, 2001, A phase I study in paediatric patients to evaluate the safety and pharmacokinetics of SPI-77, a liposome encapsulated formulation of cisplatin, Br. J. Cancer, 84, 1029, 10.1054/bjoc.2001.1723

Beijnen, 1985, Qualitative aspects of the degradation of mitomycins in alkaline solution, J. Pharm. Biomed. Anal., 3, 71, 10.1016/0731-7085(85)80008-X

Mouritsen, 1998, A new look at lipid–membrane structure in relation to drug research, Pharm. Res., 15, 1507, 10.1023/A:1011986613392

Alberts, 2008, Gynecol. Oncol., 108, 90, 10.1016/j.ygyno.2007.08.075

Joly, 2011, Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin–paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial, Gynecol. Oncol., 122, 226, 10.1016/j.ygyno.2011.04.019

Szebeni, 2012, Complement activation, immunogenicity and immune suppression as potential side effects of liposomes, 309

Gordon, 2001, Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan, J. Clin. Oncol., 19, 3312, 10.1200/JCO.2001.19.14.3312

Zhang, 2001, Liposomes in drug delivery, 783

Needham, 2000, A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model, Cancer Res., 60, 1197

Needham, 2001, The development and testing of a new temperature-sensitive drug delivery system for the treatment of solid tumors, Adv. Drug Deliv. Rev., 53, 285, 10.1016/S0169-409X(01)00233-2

Schroeder, 2007, Controlling liposomal drug release with low frequency ultrasound: mechanism and feasibility, Langmuir, 23, 4019, 10.1021/la0631668

Zucker, 2010, Optimization of vincristine–topotecan combination—paving the way for improved chemotherapy regimens by nanoliposomes, J. Control. Release, 146, 326, 10.1016/j.jconrel.2010.05.024

D. Zucker, A.V. Andriyanov, A. Steiner, U. Raviv, Y. Barenholz, Characterization of PEGylated nanoliposomes co-remotely loaded with topotecan and vincristine: relating structure and pharmacokinetics to therapeutic efficacy, J. Control. Release. (2012, this issue).

Cabanes, 1999, Enhancement of antitumor activity of polyethylene glycol-coated liposomal doxorubicin with soluble and liposomal interleukin 2, Clin. Cancer Res., 5, 687

Kedar, 1994, Delivery of cytokines by liposomes. II. Interleukin-2 encapsulated in long-circulating sterically stabilized liposomes: immunomodulatory and anti-tumor activity in mice, J. Immunother. Emphasis Tumor Immunol., 16, 115, 10.1097/00002371-199408000-00005

Kedar, 1994, Delivery of cytokines by liposomes. I. Preparation and characterization of interleukin-2 encapsulated in long-circulating sterically stabilized liposomes, J. Immunother. Emphasis Tumor Immunol., 16, 47, 10.1097/00002371-199407000-00005

Diop-Frimpong, 2011, Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors, Proc. Natl. Acad. Sci. U. S. A., 108, 2909, 10.1073/pnas.1018892108

Gabizon, 1999, Liposomal anthracyclines: from basics to clinical approval of PEGylated liposomal doxorubicin, 343

Jiang, 2011, In vitro and in vivo characterizations of PEGylated liposomal doxorubicin, Bioanalysis, 3, 333, 10.4155/bio.10.204

Tirosh, 1997, Novel synthetic phospholipid protects lipid bilayers against oxidative damage: role of hydration layer and bound water, J. Chem. Soc. Perkin 1, 2, 383, 10.1039/a601955b

Mamidi, 2010, Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?, Cancer Chemother. Pharmacol., 1

Biltonen, 1993, The use of differential scanning calorimetry as a tool to characterize liposome preparations, Chem. Phys. Lipids, 64, 129, 10.1016/0009-3084(93)90062-8

Lichtenberg, 1988, Liposomes: preparation, characterization, and preservation, Methods Biochem. Anal., 33, 337, 10.1002/9780470110546.ch7

Cui, 2007, Direct comparison of two pegylated liposomal doxorubicin formulations: Is AUC predictive for toxicity and efficacy?, J. Control. Release, 118, 204, 10.1016/j.jconrel.2006.12.002

Barenholz, 1966, Enzymatic hydrolysis of sphingolipids. II. Hydrolysis of sphingomyelin by an enzyme from rat brain, J. Biol. Chem., 241, 3731

Gatt, 1973, Enzymes of complex lipid metabolism, Annu. Rev. Biochem., 42, 61, 10.1146/annurev.bi.42.070173.000425

Gatt, 1973, Hydrolysis of sphingomyelin liposomes by sphingomyelinase, FEBS Lett., 30, 281, 10.1016/0014-5793(73)80670-2

Working, 1996, Pharmacological-toxicological expert report. CAELYX. (Stealth liposomal doxorubicin HCl), Hum. Exp. Toxicol., 15, 751

Shmeeda, 2003, Enzymatic assays for quality control and pharmacokinetics of liposome formulations: comparison with nonenzymatic conventional methodologies, Methods Enzymol., 367, 272, 10.1016/S0076-6879(03)67017-5